Bionano Genomics (BNGO) Free Cash Flow (2017 - 2026)

Bionano Genomics has disclosed Free Cash Flow across 10 years of filings, most recently posting -$5.7 million for Q1 2026.

• Free Cash Flow for Q1 2026 came in at -$5.7 million, down 106.8% year-over-year; the trailing twelve-month figure through Mar 2026 was -$19.3 million (up 55.77% YoY), and the FY2025 annual result was -$16.3 million, up 76.32% from the prior year.
• Free Cash Flow came in at -$5.7 million for Q1 2026 at Bionano Genomics, down from -$4.1 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of -$2.8 million in Q1 2025 to a low of -$36.6 million in Q2 2023.
• The 5-year median for Free Cash Flow is -$27.1 million (2023), against an average of -$20.2 million.
• Across the five-year window, Free Cash Flow sank 139.69% in 2022 and jumped 90.18% in 2025, its largest moves.
• Bionano Genomics' Free Cash Flow stood at -$33.8 million in 2022, then climbed by 9.56% to -$30.5 million in 2023, then jumped by 78.69% to -$6.5 million in 2024, then surged by 36.27% to -$4.1 million in 2025, then tumbled by 37.9% to -$5.7 million in 2026.
• The last three Free Cash Flow figures came in at -$5.7 million (Q1 2026), -$4.1 million (Q4 2025), and -$5.9 million (Q3 2025), per Business Quant data.